Ronak Savla

Corporate VC, Pharmaceutical Manufacturing, Medical Affairs, Immuno-Oncology, Drug Delivery, Angel Investing in Health Tech + Medtech

[BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech]

Stop blaming biopharma - the healthcare bill is growing from hospitals, admin, etc.

[PHD Comics @PHDcomics]

What to call your academic event

[Angelos Georgakis @angelosgeo]

Biotech fundraising feels like a wall right now.

Some strategies that will help you break through:

1. If you want advice, ask for money; if you want money, ask for advice.

Tell the investor, okay, you're saying you’re not ready, because you think we're not ready. I get it.

[Ronak Savla @RSPharmDPhD]

ChatGPT and other “large language models” make learning easier than ever. But research suggests the lessons learned are less likely to stick.

https://t.co/1U58KOPJsY

[Ronak Savla @RSPharmDPhD]

Universities look to big tech and pharma companies to fill federal funding gap.

“…aims to preserve the independence of university scientists…agreements that guarantee scientists can publish their findings with no input from companies,” Good luck https://t.co/QN4S9iwdFK

[Ronak Savla @RSPharmDPhD]

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. https://t.co/c4FysBi76Y

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

Another window into points I made in this op ed yesterday, about Chinese biotech displacing U.S. innovation:
China’s share of clinical trial starts dramatically increased — from 1% to 30% over last decade, and Chinese biotech companies are poised to overtake U.S. counterparts

[Ronak Savla @RSPharmDPhD]

Alis Biosciences to press struggling biotechs during downturn - https://t.co/P6qAB33xDu

[Ronak Savla @RSPharmDPhD]

Are any of these contrarian forms reasons to invest in biotech?

[Aswath Damodaran @AswathDamodaran]

In every market downturn, the advice to buy the dip is widely offered. I look at contrarian investing, in all its different forms, in this post, with the pluses and minuses of each one. https://t.co/Yx5Ku6UcdS

[Ronak Savla @RSPharmDPhD]

3 charts: Why there's no end in sight for venture's liquidity crisis https://t.co/GjSIThAgjG

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Drug Development Is Slowing Down After Cuts at the #FDA Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials
~3,500 workers were cut at the FDA, including Chief Medical Officer Dr. Hilary Marston and Dr. Peter Stein, who oversaw new drug approvals. Top vaccine official Dr. Peter Marks, who oversaw vaccines and biologics, was also cut
https://t.co/cc0HpinpDC

[Ronak Savla @RSPharmDPhD]

Want to see the fuller picture about biotech investments?

https://t.co/W93s3oZIOS
1Q25: 47 1st financings in the US and Europe. $1.9B of $2.6B to 6 Co's. Some are licensed Chinese assets

https://t.co/fsVloQ9oK4
2024: 6280 Chinese drugs in dev. +1200% from 2014

[Ronak Savla @RSPharmDPhD]

Cost, Speed, and Quality - China at par or ahead of Western countries. This impacts biotech and large academic medical centers that run clinical trials. It's impressive how China has overcome hurdles of innovation, bureaucracy, and policy.

 https://t.co/gYPmzQY6u6

[Ronak Savla @RSPharmDPhD]

Cuts at the FDA are forcing biotech companies that develop drugs for hard-to-treat ailments to push back clinical trials and testing https://t.co/pSN2svRiys via @WSJ

[steve usdin @steveusdin1]

FDA has lost two of its most experienced, respected oncology drug reviewers. Paul Kluetz and Marc Theoret, both deputy directors of the Oncology Center of Excellence, announced their resignations from the agency this week. BiocCentury will publish a story tomorrow.

[Ronak Savla @RSPharmDPhD]

Chinese scientist He Jiankui, who stands by a research approach that landed him in prison, is plotting a comeback as he aims to tackle Alzheimer’s disease https://t.co/CVtNW2IEVB

[John D Carroll @JohnCendpts]

Novo Nordisk is getting into the China BD act, plunking down $200M for an obesity asset. The China biotech market is open for business 24/7 and has created a full set of discount products that undermine #biotech values in the US. This is a natural progression from imitation and in-licensing to me-better and on to groundbreaking innovation. It's been 20 years in the making.
https://t.co/vPyFEowavq

[Ronak Savla @RSPharmDPhD]

Makary hints at his agenda https://t.co/VOo3fWiRBL

[Ronak Savla @RSPharmDPhD]

https://t.co/fRq7OIGw8r

[Ronak Savla @RSPharmDPhD]

Uncertainty over federal grants is endangering U.S. leadership in bioscience, which is critical to drug development and the nation’s competitiveness https://t.co/Xki6BX6oy8